Details About Generic Salt ::  Cefoteta

Main Medicine Class:: Antibiotic,cephalosporin   

(SEFF-oh-tee-tan die-SO-dee-uhm)

Cefotan

Class: Antibiotic/cephalosporin

Drugs Class ::

 Action Inhibits mucopeptide synthesis in bacterial cell wall.

Indications for Drugs ::

 Indications Treatment of infections of urinary tract, lower respiratory tract, skin and skin structures, bone and joint; treatment of gynecological infections; treatment of intra-abdominal infections due to susceptible strains of specific microorganisms; perioperative prophylaxis. Concommitant antibiotic therapy: If cefotetan and an aminoglycoside are to be used concomitantly, carefully monitor renal function, especially if higher dosages of the aminoglycoside are to be administered or if therapy is to be prolonged, because of the potential nephrotoxicity and ototoxicity of aminoglycosides.

Drug Dose ::

 Route/Dosage

Infection

ADULTS: IV/IM 1–2 g q 12 hr (life-threatening infections: up to 3 g q 12 hr) for 7–10 days.

Urinary Tract Infection

ADULTS: IV/IM 500 mg every 12 hrs, 1 or 2 g every 24 hours, 1 or 2 g ever 12 hrs.

Perioperative Prophylaxis

ADULTS: IV 1–2 g 30–60 min prior to surgery. In cesarean section, give dose as soon as umbilical cord is clamped.

Contraindication ::

 Contraindications Hypersensitivity to cephalosporins.

Drug Precautions ::

 Precautions

Pregnancy: Category B. Lactation: Excreted in breast milk. Children: Safety and efficacy in children not established. Hypersensitivity: Reactions range from mild to life-threatening. Administer drug with caution to penicillin-sensitive patients due to possible crossreactivity. Pseudomembranous colitis: Should be considered in patients who develop diarrhea. Renal impairment: Use drug with caution in patients with renal impairment. Dosage adjustment based on renal function may be required. Superinfection: May result in bacterial or fungal overgrowth of nonsusceptible microorganisms.

Drug Side Effects ::

 Adverse Reactions

GI: Nausea; vomiting; diarrhea; anorexia; abdominal pain or cramps; flatulence; colitis, including pseudomembranous colitis. GU: Pyuria; renal dysfunction; dysuria; reversible interstitial nephritis; hematuria; toxic nephropathy. HEMA: Eosinophilia; neutropenia; lymphocytosis; leukocytosis; thrombocytopenia; decreased platelet function; anemia; aplastic anemia; hemorrhage. HEPA: Hepatic dysfunction; abnormal liver function test results. OTHER: Hypersensitivity, including Stevens-Johnson syndrome, erythema multiforme, toxic epidermal necrolysis; candidal overgrowth; serum sickness-like reactions (eg, skin rashes, polyarthritis; arthralgia, fever); phlebitis, thrombophlebitis and pain at injection site.

Drug Mode of Action ::  

 Action Inhibits mucopeptide synthesis in bacterial cell wall.

Drug Interactions ::

 Interactions

Alcohol: Acute alcohol intolerance (disulfiram-like reaction) may occur up to 3 days after last dose of cefotetan. Aminoglycosides: Increased risk of nephrotoxicity. Anticoagulants, oral: Increased anticoagulant effect; bleeding complications may occur. INCOMPATIBILITIES: Aminoglycosides: Do not add aminoglycosides to cefotetan solutions because inactivation of both drugs may result; administer at separate sites if concurrent therapy is indicated.

Drug Assesment ::

 Assessment/Interventions

• Obtain patient history, including drug history and any known allergies. Note allergy to cephalosporins or penicillins.
• Obtain specimens for culture and sensitivity before beginning therapy and periodically during treatment.
• Monitor renal function carefully during treatment.
• This is particularly important if cefotetan is administered concomitantly with an aminoglycoside due to potential nephrotoxicity and ototoxicity.
• Monitor for coagulation abnormalities. Elevate prothrombin time or abnormal platelet count may occur. If bleeding occurs and PT is prolonged, vitamin K may be indicated.
• Monitor for signs of infection, especially fever, and for positive response to antibiotic therapy.
• Assess for signs and symptoms of anaphylaxis (shortness of breath, wheezing, laryngeal spasm). Have resuscitation equipment available.
• Assess for signs of superinfection, such as vaginitis or stomatitis.
• Assess for diarrhea with blood or pus, which may be symptom of pseudomembranous colitis. Symptoms may occur after antibiotic treatment.
• Monitor IV site for infiltration, infection and thrombophlebitis.

Drug Storage/Management ::

 Administration/Storage

• Reconstituted solution may be light yellow to amber. Do not administer if solution is cloudy or precipitate is present.
• For IM injection, drug may be reconstituted with 0.5% or 1% lidocaine without epinephrine to minimize pain on injection.
• When giving by IM route, inject deeply into large muscle (eg, upper outer quadrant of gluteus muscle or lateral thigh). Massage well.
• When giving by IV route, administer slowly over 3–5 min. Reconstituted drug may be diluted in 50–100 ml of D5W or 0.9% sodium chloride and infused over 20–30 min. Change IV sites q 48–72 hr.
• For perioperative prophylaxis, administer cefotetan 50–120 min before surgical incision.
• Store sterile powder at room temperature and protect from light.

Drug Notes ::

 Patient/Family Education

• Instruct patient to check body temperature daily. If fever persists for more than a few days or if high fever (> 102°F) or shaking chills are noted, physician should be notified immediately.
• Advise patient to maintain normal fluid intake while using this medication.
• Advise patient not to drink alcoholic beverages or take alcohol-containing medications while taking cefamandole nafate and for several days after discontinuing drug.
• Advise diabetic patient to use enzyme-based tests (eg, Clinistix, Testape) for monitoring urine glucose because drug may give false results with other tests.
• Instruct patient to report these symptoms to physician: nausea, vomiting, diarrhea, skin rash, hives, sore throat, bruising, bleeding, muscle or joint pain.
• Warn patient that diarrhea that contains blood or pus may be a sign of serious disorders. Tell patient to seek medical care and not to treat at home.
• Instruct patient to seek emergency care if wheezing or difficulty in breathing occurs.
• Instruct patient to report signs of superinfection: black “furry” tongue, white patches in mouth, foul-smelling stools, vaginal itching or discharge.

Disclaimer ::

The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.